The UK and US have agreed to a major trade agreement that will maintain zero levies on British medicine products being sold in the American market.
Agreement Details of the Pact
As part of the deal, the UK has agreed to raise spending on drugs through the NHS. This move ensures that tariffs on these key exports will be held at zero for a duration of three years.
This development follows recent warnings to hike tariffs on branded pharmaceutical products, with increases mentioned as high as 100%.
"This deal with the UK reinforces the global environment for cutting-edge drugs and establishes much-needed fairness to transatlantic medicine commerce," a release noted.
Economic Significance
Medicines represent one of the the United Kingdom's largest goods shipped to the US, which is by far the largest buyer for major companies like GSK and AstraZeneca.
Statistics indicate that in the one-year period leading up to last September, the UK shipped pharmaceutical products worth billions to the US. This amount accounted for nearly one-fifth of total UK exports in that timeframe.
"This agreement protects employment, boosts capital expenditure and facilitates the UK to emerge as a worldwide center for medical research," a minister stated.
Specific British Pledges
The agreement involves several key pledges from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it judges new therapies to be prohibitively costly by twenty-five percent.
- Higher Drug Budget: There is a goal to double total health service expenditure on drugs from 0.3 percent of Gross Domestic Product to 0.6% over the following ten-year period.
- Payback Limit: The amount pharmaceutical firms must return to the NHS to prevent overspending will be restricted at 15%. Previously, repayments exceeded 20%.
Industry Background
The pact follows a protracted row between the drug companies and the ministers over spending levels and approval rates.
These tensions were exacerbated by claims that American patients were charged a premium for the identical medicines than people in the other developed nations.
Over the last 18 months, several large pharmaceutical investments in the UK have been halted or abandoned, while substantial investments have been pledged toward US facilities.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its expenditure on drugs had decreased as a proportion of its total funding over the past decade.
